CN103054895A - Medicine composition for preventing and treating obesity - Google Patents
Medicine composition for preventing and treating obesity Download PDFInfo
- Publication number
- CN103054895A CN103054895A CN201310015793XA CN201310015793A CN103054895A CN 103054895 A CN103054895 A CN 103054895A CN 201310015793X A CN201310015793X A CN 201310015793XA CN 201310015793 A CN201310015793 A CN 201310015793A CN 103054895 A CN103054895 A CN 103054895A
- Authority
- CN
- China
- Prior art keywords
- treatment
- verbascoside
- radix rehmanniae
- catalpol
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a medicine composition for preventing and treating obesity. The medicine composition is characterized by containing 0.03-10 parts of catalpol, 10-50 parts of rhizoma rehmanniae polysaccharides and 0.02-0.3 part of verbascoside. The medicine composition has obvious effects of preventing and treating obesity and does not have a side effect.
Description
Technical field
The present invention relates to medicine, particularly a kind of prevention and the fat pharmaceutical composition for the treatment of belong to medical technical field.
Background technology
According to the data that World Health Organization (WHO) announces, the whole world has had the adult above 1,000,000,000 overweight, and it is the obesity patient that 300,000,000 people are wherein arranged, and these overweight peoples become the main force of some fat metabolic syndromes.Obesity is accompanied by a series of metabolic syndrome such as insulin resistance, П-diabetes, and hypertension, atherosclerosiss etc. become the disease that threatens the whole mankind.Therefore, how to prevent and treat obesity and correlated metabolism diseases thereof, become problem demanding prompt solution.
Radix Rehmanniae is the tuber of scrophulariaceae rehmannia glutinosa plant Rehmannia glutinosa L-ibosch., begins to be stated from Shennong's Herbal, classifies as top gradely, is one of conventional Chinese medicine.At present Radix Rehmanniae comparatively common clinical being used as medicine, be divided into Radix Rehmanniae, Radix Rehmanniae, Radix Rehmanniae Preparata, Radix Rehmanniae charcoal, Radix Rehmanniae Preparata charcoal etc.After Radix Rehmanniae was processed through different concocting methods, corresponding change also can occur in its nature and flavor, effect.Cold in nature, the sweet-bitter flavor of Radix Rehmanniae is take clearing away heat and promoting production of body fluid, cooling blood for hemostasis as main.Radix Rehmanniae is name Radix Rehmanniae or Radix Rehmanniae after place of production processing is dried, and its cold in nature, sweet in the mouth is take clearing away heat and cooling blood, YIN nourishing and the production of body fluid promoting as main.Radix Rehmanniae is the name Radix Rehmanniae Preparata after steaming, and its property is by the cold temperature that turns, and its flavor turns sweet by hardship, and its effect is filled out marrow as main by turning clearly benefit take nourishing YIN and supplementing blood, beneficial essence.
The pharmacological research of Radix Rehmanniae has been subject to paying close attention to widely in recent years, and is widely used in clinical.Be used for hemostasis, be used for diabetes, be used for cardiovascular and cerebrovascular disease, be used for hypertension, be used for nephritis, be used for dull-witted, be used for urinary system, be used for oral ulcer etc.
We find through long-term research, and the prevention of lyophilizing Radix Rehmanniae and treatment obesity have preferably curative effect.
Summary of the invention
The purpose of this invention is to provide a kind of prevention and fat little, the effective pharmaceutical composition of taking dose for the treatment of.
A kind of prevention and the fat pharmaceutical composition for the treatment of contain catalpol, Dihuang polysaccharide, verbascoside.
A kind of prevention that the present invention is above-mentioned and the pharmaceutical composition prioritization scheme for the treatment of obesity are for containing catalpol, stachyose, verbascoside.
A kind of prevention and the fat pharmaceutical composition for the treatment of that the present invention is above-mentioned contain catalpol 0.03-10 part, Dihuang polysaccharide 10-50 part, verbascoside 0.02-0.3 part.
A kind of prevention that the present invention is above-mentioned and the pharmaceutical composition prioritization scheme for the treatment of obesity are for containing catalpol 0.03-10 part, stachyose 3-16 part, verbascoside 0.02-0.3 part.
The above-mentioned Dihuang polysaccharide of the present invention comprises stachyose, Raffinose, Portugal's mannotriose, verbascose and galactose.
A kind of prevention of the present invention and the fat pharmaceutical composition for the treatment of, part is by weight, if part in grams, more than consists of 3-5 days taking dose of adult.
Above-mentioned each of the present invention forms and is by weight as proportioning, when producing, can increase or reduce according to corresponding ratio, can be with kilogram or take ton as unit such as large-scale production, weight can increase or reduce, but the crude drug weight proportion constant rate between the each component, the taking dose of being grown up a day is constant.
On the basis of existing technology, the above-mentioned a kind of prevention of the present invention and the fat pharmaceutical composition of the treatment raw material that preferably contains Radix Rehmanniae obtains by extraction.
So far finished the present invention, a kind of prevention that the present invention is above-mentioned and the fat pharmaceutical composition for the treatment of, prevention and treatment are fat evident in efficacy, have no side effect.Below further set forth the present invention prevention and the fat beneficial effect for the treatment of with clinical trial.
1, physical data simple obesity patient 66 examples meet the diagnostic criteria of the special Asia adult physical fitness volume index (BMI) 〉=25 that proposes of international obesity standard in 2000, and are divided into two groups by the table of random number method.Treatment group 34 examples, matched group 32 examples learn to be processed by statistics, two groups of sexes, mean age, weight, BMI isobase data, there was no significant difference has comparability.
2, two groups of Therapeutic Method are all adhered to treatment according to weight-reducing diet, exercise prescription regulation.Weight-reducing diet prescription: 1. determine energy requirment every day; 2. determine the distribution of three large nutrients: carbohydrate accounts for 50%-60%, protein≤30%, high-cellulose diet; 3. every days 3, meal was assigned as 2/5,2/5,1/5.Exercise prescription: aerobatic exercise, comprise hurry up, swim, jog, dancing etc., training time 60min/ time, 3 times weekly.
Matched group: adhere to weight-reducing diet, exercise prescription predetermined treatment.
Treatment group: take tablet of the present invention on the basis of adhering to weight-reducing diet, exercise prescription predetermined treatment, 3 piece/timess, 3 times/days.
Require inactive other all relevant Chinese and western drugses in the patient treatment process, 2 months is 1 course for the treatment of.
3, the observational technique all cases is all filled in the observation registration form in detail, follow up a case by regular visits to weekly and survey weight 1 time, and before and after treatment is measured respectively in medical history, health check-up following index: 1. height, weight, BMI, waistline (WC), waist-to-hipratio (WHR), fat percentage; 2. fasting glucose (FBG), T-CHOL (TC), triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-C), HDL-C (HDL-C), insulin (INS).
4, two groups of indices all were improved in varying degrees after two groups of patient body quality of result, BMI, WC, WHR, fat percentage changed treatment, weight, BMI, WC, WHR, fat percentage, matched group is all meaningful with the front comparing difference for the treatment of, treatment group has significant with the front comparing difference for the treatment of, and namely the treatment group curative effect is better than matched group.Two groups of indices all were improved in varying degrees after two groups of FBG, TC, TG, HDL-C, LDL-C, INS changed treatment, and relatively, indices all has significant difference after two groups of treatments, and namely the treatment group curative effect obviously is better than matched group.
The specific embodiment
Embodiment 1
Getting the lyophilizing Radix Rehmanniae is the solvent reflux, extract, with methanol, reclaim methanol, add water and stir evenly, n-butanol extraction, butanol solution concentrating under reduced pressure, dissolving adds diethyl ether, active carbon kieselguhr mixed column on the insoluble matter take the ethanol of 1-10% as eluant, is collected respectively the eluent that contains catalpol, verbascoside, dry respectively, get catalpol, verbascoside.
Get Radix Rehmanniae, use water extraction 2 times, add 8 times of water gagings for the first time, extracted 1.5 hours, and added 6 times of water gagings for the second time and extracted merge extractive liquid, 1 hour, filter, be concentrated into Radix Rehmanniae etc. heavyly, add the dehydrated alcohol of 3 times of weight, 4 ℃ of low temperature are placed and are spent the night, as seen white cotton-shaped crude polysaccharides is separated out, centrifugal, collecting precipitation thing, the dry crude polysaccharides that gets.
Get catalpol 10kg, Dihuang polysaccharide 10kg, verbascoside 0.02kg, mixing, starch slurry is granulated, drying, granulate, the adding Pulvis Talci is an amount of, tabletting, prevention of obesity was taken 100 days for 30 people.
Embodiment 2
Get catalpol 30g, stachyose 3kg, verbascoside 20g, add carboxymethyl starch sodium, gelatinized corn starch is granulated, drying, and arrangement, the adding Pulvis Talci is an amount of, mixing, tabletting gets 9000.Fat patient, each 3, every day 3 times.
Embodiment 3
Get Radix Rehmanniae 100kg, use ethanol percolate extraction, the extracting solution Recycled ethanol must contain the Radix Rehmanniae extract 5kg of catalpol, contains catalpol 0.5kg through chemical examination.
Medicinal residues water extraction 2 times add 8 times of water gagings for the first time, extract 1.5 hours, add 6 times of water gagings for the second time and extract 1 hour, merge extractive liquid, filters, and is concentrated, drying must contain the Radix Rehmanniae extract 15kg of Dihuang polysaccharide and verbascoside, contains Dihuang polysaccharide 10kg, verbascoside 20kg through chemical examination.
Get the Radix Rehmanniae extract that contains catalpol, the Radix Rehmanniae extract that contains Dihuang polysaccharide and verbascoside, mixing, 50% alcohol granulation, drying, the Capsules of packing into gets capsule.
Embodiment 4
Get catalpol 10kg, Dihuang polysaccharide 10kg, verbascoside 0.3kg, add starch, mixing is granulated, drying, and arrangement, the adding Pulvis Talci is an amount of, mixing, tabletting gets 9000.Fat patient, each 3, every day 3 times.
Embodiment 5
Get catalpol 5kg, Dihuang polysaccharide 25kg, verbascoside 0.1kg, add dextrin, mixing is granulated, drying, and arrangement gets granule.
Embodiment 6
Get catalpol 5kg, stachyose 3kg, verbascoside 0.1kg, add dextrin, mixing is granulated, drying, and arrangement gets granule.
Embodiment 7
Get catalpol 10kg, stachyose 16kg, verbascoside 0.3kg, add starch, mixing is granulated, drying, and arrangement, the adding Pulvis Talci is an amount of, mixing, tabletting gets 9000.Fat patient, each 3, every day 3 times.
Embodiment 8
Get catalpol 10kg, stachyose 12kg, verbascoside 0.3kg, add starch, mixing is granulated, drying, and arrangement, the adding Pulvis Talci is an amount of, mixing, tabletting gets 9000.Fat patient, each 3, every day 3 times.
Claims (4)
1. a pharmaceutical composition that prevents and treat obesity is characterized in that containing catalpol, Dihuang polysaccharide, verbascoside.
2. according to claim 1 a kind of prevention and the fat pharmaceutical composition for the treatment of is characterized in that containing catalpol, stachyose, verbascoside.
3. according to claim 1 a kind of prevention and the fat pharmaceutical composition for the treatment of is characterized in that containing catalpol 0.03-10 part, Dihuang polysaccharide 10-50 part, verbascoside 0.02-0.3 part.
4. according to claim 2 a kind of prevention and the fat pharmaceutical composition for the treatment of is characterized in that containing catalpol 0.03-10 part, stachyose 3-16 part, verbascoside 0.02-0.3 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310015793XA CN103054895A (en) | 2013-01-16 | 2013-01-16 | Medicine composition for preventing and treating obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310015793XA CN103054895A (en) | 2013-01-16 | 2013-01-16 | Medicine composition for preventing and treating obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103054895A true CN103054895A (en) | 2013-04-24 |
Family
ID=48097991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310015793XA Pending CN103054895A (en) | 2013-01-16 | 2013-01-16 | Medicine composition for preventing and treating obesity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103054895A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103622980A (en) * | 2013-12-12 | 2014-03-12 | 宁夏医科大学 | Application of cistanche phenylethanoid glycoside compound to preparation of drugs for treating osteoporosis and drug composition containing cistanche phenylethanoid glycoside compound |
| CN107982318A (en) * | 2017-12-13 | 2018-05-04 | 广西中医药大学 | A kind of Traditional Chinese medicine for decreasing blood sugar compound |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058712A (en) * | 2009-11-13 | 2011-05-18 | 上海玉森新药开发有限公司 | Rehmannia stem and leaf extract and preparation method and application thereof |
| CN102145076A (en) * | 2010-02-05 | 2011-08-10 | 北京三有利科技发展有限公司 | Rehmannia and new use of extract of rehmannia |
-
2013
- 2013-01-16 CN CN201310015793XA patent/CN103054895A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058712A (en) * | 2009-11-13 | 2011-05-18 | 上海玉森新药开发有限公司 | Rehmannia stem and leaf extract and preparation method and application thereof |
| CN102145076A (en) * | 2010-02-05 | 2011-08-10 | 北京三有利科技发展有限公司 | Rehmannia and new use of extract of rehmannia |
Non-Patent Citations (2)
| Title |
|---|
| LIN JIANG,ET: "《Rehmannia inhibits adipocyte differentiation and adipogenesis》", 《BIOCHEMICAL AND BIOPHYSICAL TESEARCH COMMUNICATIONS》 * |
| 王宏洁等: "鲜地黄化学成分的分离鉴定及活性作用初探", 《中国实验方剂学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103622980A (en) * | 2013-12-12 | 2014-03-12 | 宁夏医科大学 | Application of cistanche phenylethanoid glycoside compound to preparation of drugs for treating osteoporosis and drug composition containing cistanche phenylethanoid glycoside compound |
| CN107982318A (en) * | 2017-12-13 | 2018-05-04 | 广西中医药大学 | A kind of Traditional Chinese medicine for decreasing blood sugar compound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104856968B (en) | A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof | |
| CN102178779B (en) | Method for preparing capsules containing prepared rehmannia root, white paeony root, Chinese angelica and szechuan lovage rhizome and application | |
| CN104585743B (en) | A kind of Herba Cistanches effervescent tablet and its preparation process | |
| CN102973719A (en) | Traditional Chinese medicine health-care food with bowel relaxing function and preparation method thereof | |
| CN105695537A (en) | Preparation method of glycosylation enteromorpha oligosaccharide for reducing glucose level and regulating intestinal flora | |
| CN102319357B (en) | Lipid-lowering dispersible tablets and preparation technology thereof | |
| CN103054895A (en) | Medicine composition for preventing and treating obesity | |
| CN101766707B (en) | Chinese medicine preparation for treating oral diseases | |
| CN101371875B (en) | Method for extracting and preparing total saponin of compound abnormal savda mature agent | |
| CN102940709B (en) | Medicine composition for treating gout | |
| CN102614457B (en) | Preparation method of breast recovering tablet | |
| CN115531463A (en) | Traditional Chinese medicine for treating hyperlipidemia | |
| CN103239551A (en) | Freeze-dried radix rehmanniae for preventing and curing obesity | |
| CN102309705B (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN102940747B (en) | Medicine composition for treating gout | |
| CN100444835C (en) | Tendon-relaxing blood circulation-activating capsule and preparation process thereof | |
| CN113827660A (en) | Traditional Chinese medicine composition for reducing blood sugar and blood fat and preparation method thereof | |
| CN101371876B (en) | Method for extracting and preparing total polysaccharide of compound abnormal savda mature agent | |
| CN103127358B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method | |
| CN103536738B (en) | Preparation method of compound black-bone chicken preparation | |
| CN108553559B (en) | Formula and preparation method of vegetable and fruit extract for preventing and treating type II diabetes | |
| CN100446800C (en) | Chinese traditional medicine composition | |
| CN103055099A (en) | Freeze-dried pharmaceutical composition for preventing and treating obesity | |
| CN105596663A (en) | Weight-losing drug | |
| CN104547506A (en) | Traditional Chinese medicine preparation containing ginseng ultrafine powder and preparation method of traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130424 |